Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Melanoma 9Neoplasms 7Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Colorectal Neoplasms 5Lymphoma 4Liver Neoplasms 4Lung Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mesothelioma 2Locally Advanced Rectal Cancer 2Hematologic Diseases 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Adenocarcinoma 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Solid Tumor, Adult 1

Interventions

Gemcitabine 39Cisplatin 24Oxaliplatin 15pembrolizumab 12Capecitabine 12Fluorouracil 9Leucovorin 7Albumin-Bound Paclitaxel 7lenvatinib 6Radiofrequency Ablation 6Panitumumab 6130-nm albumin-bound paclitaxel 6Irinotecan 5Bevacizumab 5durvalumab 4Taxes 4Nivolumab 4Hepatectomy 4Drug Therapy 4tremelimumab 3apatinib 3Radiosurgery 3Platinum 3Injections 3Floxuridine 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3trametinib 2spartalizumab 2sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Cholangiocarcinoma × spartalizumab × Clear all
NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Symphogen A/S

Phase 1 Completed
48 enrolled
GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04641871 2024-06-26

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Symphogen A/S

Phase 1 Completed
78 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡